Degenerative Disc Disease Treatment Market - By Product Type (Drugs {Acetaminophen, NSAIDs, Muscle Relaxants, Steroids, Route of Administration [Oral, Injectable]} Devices {Cervical, Lumbar}), By End-use & Forecast 2023 - 2032

Degenerative Disc Disease Treatment Market Size

Degenerative Disc Disease Treatment Market size accounted for USD 24 billion in 2022 and is estimated to grow at 7.2% to reach USD 49.7 billion by 2032. Growing prevalence of degenerative bone diseases will positively influence the market growth.
 

For instance, in 2021, according to the Centers of Disease Control and Prevention (CDC), adults aged 65 years and above are more affected by degenerative bone disease. The CDC also estimated that nearly 78 million (26%) of U.S. adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040. This indicates that there will huge number of patient pool suffering from degenerative bone disease. Such high prevalence of the disease will increase the product demand.
 

Degenerative disc disease (DDD) is a condition that affects the intervertebral discs in the spine, causing them to degenerate and lose their flexibility over time. Degenerative disc disease (DDD) treatment involves a stepwise approach to manage symptoms. Conservative measures like physical therapy, pain medications, and lifestyle modifications are commonly employed. In some cases, epidural steroid injections may be used to reduce inflammation. Also, surgical interventions like discectomy, spinal fusion, or artificial disc replacement may be considered for severe cases. The choice of treatment depends on symptom severity, disc degeneration, and individual health.
 

COVID-19 Impact

The COVID-19 pandemic has severely impacted the global economies with all the sectors witnessing a significant slump during 2020. The healthcare sector was one of the most severely impacted sectors during the pandemic owing to tremendous pressure on the healthcare systems to contain the spread of infection. Various non-essential surgical procedures were halted during the pandemic to control the spread of infection. As the degenerative disc disease procedures are noted to be non-emergency, these surgical procedures were suspended and postponed indefinitely during pandemic. Thus, low demand was observed for degenerative disc disease amidst the pandemic.
 

Degenerative Disc Disease Treatment Market Trends

Increasing rate of geriatric population is one of the major factors propelling the market demand. Rising prevalence of bone degenerative disorders such as osteoporosis and rheumatoid arthritis in the geriatric population is expected to boost the demand of degenerative disc disease treatment. Furthermore, geriatric population is more susceptible to the bone degenerative diseases such as spinal stenosis, osteophyte formation, osteomyelitis, degenerative disc herniation among others owing to immunocompromised nature of aging and increasing number of chronic comorbidities.
 

Degenerative Disc Disease Treatment Market Analysis

The treatment of degenerative disc disease (DDD) involves surgical interventions that often come with a high cost. Procedures such as discectomy, spinal fusion, artificial disc replacement are expensive, impacting access for patients with limited financial resources and inadequate insurance coverage. Thus, high cost of surgical interventions may act as a barrier, hindering patients from pursuing these treatment options and potentially limiting the growth of the DDD treatment industry. Also, post-surgical complications such as bleeding, nerve damage and inflammation may possibly impede the market share.
 

By product type, the degenerative disc disease treatment market is classified into drugs and devices. The devices segment accounted over 51% of the market share in 2022 and is projected to witness robust growth over the analysis timeframe. Degenerative disc disease (DDD) treatment involves the use of specialized devices in different areas of the spine that offers various benefits for managing DDD effectively. Cervical spine devices such as artificial discs provide stability, restore disc height and maintain proper alignment by reducing pain and improving functionality in the neck. Lumbar spine devices, such as interbody cages, pedicle screws address instability and nerve compression and offer support and restoring stability in the lower back.
 

Based on end-use, the degenerative disc disease treatment market is segmented into hospitals, clinics and others. The hospitals are expected to register USD 26.6 billion in 2032. Hospitals include specialized departments with skilled surgeons and advanced diagnostic technologies. Multidisciplinary care teams ensure personalized treatment plans and coordinated care for degenerative disc treatment that enables to attain improved patient outcomes. Furthermore, growing technological advancements in degenerative disc disease treatment and increase in hospital admissions for surgeries and treatments will further stimulate the market expansion.
 

North America degenerative disc disease treatment market accounted for over 57% business share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. Increasing prevalence of DDD, coupled with advancements in medical technology and growing geriatric population has significantly fueled the market size in the North America region. Furthermore, presence of key market players and favorable government regulation for novel drugs and devices development is expected to proliferate the regional market outlook.
 

Degenerative Disc Disease Treatment Market Share

Major market players operating in the degenerative disc disease treatment market include

• Pfizer Inc
• Medtronic plc
• Novartis AG
• B. Braun Melsungen AG 

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
 

Some of the recent industry developments:

• In January 2023, DiscGenics, Inc announced that the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to its Injectable Disc Cell Therapy (IDCT or rebonuputemcel), an injectable, allogeneic discogenic progenitor cell therapy for the treatment of symptomatic lumbar degenerative disc disease (DDD). This development represents a critical validation of the company's novel approach to utilize a manufactured live progenitor cell population derived from donated adult human intervertebral disc tissue to treat disc degeneration, thereby offering competitive advantage.
   
• In March 2022, Spine BioPharma Inc received USD 13 million series B round of funding for injectable treatment for degenerative disc disease. This funding helped the company to develop SB-01 treatment, a first-in-class therapeutic for the treatment of degenerative disc disease, thereby drive revenue growth.
   

The degenerative disc disease treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Product Type

• Drugs
• Acetaminophen
• NSAIDs
• Muscle Relaxants
• Steroids
• Drugs by route of administration
  • Oral
  • Injectable

• Devices
• Cervical Spine
• Lumbar Spine
• Spinal Fusion
• Thoracic Spine

By End-use

• Hospitals
• Clinics
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • The Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Malaysia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • Chile
  • Peru
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Iran
  • Rest of MEA